Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Chemical Research in Toxicology
|
April 6, 2019
Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans
Dieter Lang, Martin Radtke, Michaela Bairlein
European Journal of Drug Metabolism and Pharmacokinetics
|
March 4, 2020
Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications
Roland Heinig, Michael Gerisch, Michaela Bairlein, et al.
Toxicology
|
May 21, 2025
Predicting in vitro assays related to liver function using probabilistic machine learning
Flavio M Morelli, Marian Raschke, Natalia Jungmann, et al.
Current Drug Metabolism
|
August 18, 2023
<i>In vivo</i> Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites
Simone I Schulz, Dieter Lang, Gabriele Schmuck, et al.
Nature Methods
|
September 15, 2009
Proteomics strategy for quantitative protein interaction profiling in cell extracts
Kirti Sharma, Christoph Weber, Michaela Bairlein, et al.
Molecular Cell
|
August 12, 2008
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle
Henrik Daub, Jesper V Olsen, Michaela Bairlein, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
October 2, 2019
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Christian Zurth, Mikko Koskinen, Robert Fricke, et al.
Journal of Medicinal Chemistry
|
November 21, 2019
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor <i>N</i>-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile
Stefan Werner, Stefanie Mesch, Roman C Hillig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 17, 2015
Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper
Eugenia Kraynov, Amrita V Kamath, Markus Walles, et al.
Journal of Medicinal Chemistry
|
September 24, 2020
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Hartmut Beck, Tobias Thaler, Daniel Meibom, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Chemical Research in Toxicology
|
April 6, 2019
Highly Variable Expression of CYP1A1 in Human Liver and Impact on Pharmacokinetics of Riociguat and Granisetron in Humans
Dieter Lang, Martin Radtke, Michaela Bairlein
European Journal of Drug Metabolism and Pharmacokinetics
|
March 4, 2020
Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications
Roland Heinig, Michael Gerisch, Michaela Bairlein, et al.
Toxicology
|
May 21, 2025
Predicting in vitro assays related to liver function using probabilistic machine learning
Flavio M Morelli, Marian Raschke, Natalia Jungmann, et al.
Current Drug Metabolism
|
August 18, 2023
<i>In vivo</i> Metabolism of Nifurtimox and the Drug-Drug Interaction Potential Including its Major Metabolites
Simone I Schulz, Dieter Lang, Gabriele Schmuck, et al.
Nature Methods
|
September 15, 2009
Proteomics strategy for quantitative protein interaction profiling in cell extracts
Kirti Sharma, Christoph Weber, Michaela Bairlein, et al.
Molecular Cell
|
August 12, 2008
Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle
Henrik Daub, Jesper V Olsen, Michaela Bairlein, et al.
European Journal of Drug Metabolism and Pharmacokinetics
|
October 2, 2019
Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
Christian Zurth, Mikko Koskinen, Robert Fricke, et al.
Journal of Medicinal Chemistry
|
November 21, 2019
Discovery and Characterization of the Potent and Selective P2X4 Inhibitor <i>N</i>-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide (BAY-1797) and Structure-Guided Amelioration of Its CYP3A4 Induction Profile
Stefan Werner, Stefanie Mesch, Roman C Hillig, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
December 17, 2015
Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper
Eugenia Kraynov, Amrita V Kamath, Markus Walles, et al.
Journal of Medicinal Chemistry
|
September 24, 2020
Potent and Selective Human Prostaglandin F (FP) Receptor Antagonist (BAY-6672) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Hartmut Beck, Tobias Thaler, Daniel Meibom, et al.
Page
of 1